越南SOAR 2020-21监测:肺炎链球菌与流感嗜血杆菌耐药率
该研究分析了2020-21年越南胡志明市两家医院分离的144株肺炎链球菌和191株流感嗜血杆菌,采用CLSI、EUCAST及PK/PD折点判读药敏。结果显示肺炎链球菌对青霉素、大环内酯类及部分头孢菌素耐药率高,流感嗜血杆菌中β-内酰胺酶阴性氨苄西林耐药(BLNAR)比例高,氟喹诺酮敏感性约88%-89%。
要点
- 肺炎链球菌青霉素敏感率仅6.3%(口服/低剂量折点)至69.4%(静脉/高剂量折点)。
- 流感嗜血杆菌BLNAR占β-内酰胺酶阴性株的74.6%-87.7%。
- 流感嗜血杆菌对头孢曲松全部敏感,但对头孢噻肟EUCAST敏感率仅15.7%。
核心结论
- 越南两家医院肺炎链球菌对青霉素和大环内酯类耐药率高,流感嗜血杆菌中BLNAR比例高。
- 流感嗜血杆菌对氟喹诺酮敏感性为88.0%-89.0%(CLSI)。
研究设计与样本
- 2020-21年从越南胡志明市两家医院收集社区获得性呼吸道感染分离株。
- 共纳入144株肺炎链球菌和191株流感嗜血杆菌,采用CLSI肉汤微量稀释法测定MIC。
- 药敏结果分别按CLSI、EUCAST(剂量特异性)和PK/PD折点判读。
主要发现
- 肺炎链球菌对阿莫西林/克拉维酸(2:1)敏感率:CLSI 56.3%,EUCAST高剂量25.7%,PK/PD高剂量阿莫西林(4 g/0.25 g/day)78.5%。
- 肺炎链球菌对头孢曲松敏感率:EUCAST高剂量91.7%,CLSI或PK/PD 50.7%。
- 肺炎链球菌对头孢噻肟敏感率:CLSI 61.8%,EUCAST 29.9%。
- 肺炎链球菌对四环素类、大环内酯类和复方磺胺甲噁唑敏感率仅5.6%-16.7%。
- 流感嗜血杆菌对阿莫西林/克拉维酸敏感率:EUCAST 45.5%,CLSI 32.5%,高剂量PK/PD 82.8%。
关键数值与推荐
- 肺炎链球菌青霉素敏感率:CLSI静脉/EUCAST高剂量69.4%,CLSI口服/EUCAST低剂量6.3%。
- 流感嗜血杆菌β-内酰胺酶阴性株中,BLNAR比例按EUCAST为87.7%,按CLSI为74.6%。
- 流感嗜血杆菌对氟喹诺酮、大环内酯和四环素敏感率62.0%-89.5%(CLSI、EUCAST),大环内酯PK/PD敏感率3.7%-5.8%。
- 流感嗜血杆菌对头孢曲松所有折点均敏感,对头孢噻肟CLSI和PK/PD均敏感,EUCAST敏感率15.7%。
临床怎么用
- 经验性治疗社区获得性呼吸道感染时,需考虑当地肺炎链球菌对青霉素和大环内酯类的高耐药率。
- 流感嗜血杆菌BLNAR高发,氨苄西林不宜作为经验性用药。
- 高剂量阿莫西林/克拉维酸或头孢曲松可能对部分耐药株有效,但需结合药敏结果。
局限性
- 仅纳入越南胡志明市两家医院,样本量有限,代表性受限。
- 未报告患者临床特征、感染部位及既往抗菌药物使用史。
- 药敏折点判读差异可能导致敏感率比较复杂,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antibiotic susceptibility determination of Streptococcus pneumoniae and Haemophilus influenzae from community-acquired respiratory infections collected in 2020-21 from two hospitals in Ho Chi Minh City, Vietnam. METHODS: MICs were determined by CLSI broth microdilution; susceptibility was interpreted based on CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 144 S. pneumoniae and 191 H. influenzae isolates were collected. S. pneumoniae susceptibility to amoxicillin and amoxicillin/clavulanic acid (2:1) was 56.9% and 56.3% (CLSI), 29.2% and 25.7% (EUCAST high-dose) and 78.5% using high-dose amoxicillin (4 g/0.25 g/day, PK/PD). Susceptibility to ceftriaxone was 91.7% by EUCAST (high-dose) and 50.7% by CLSI or PK/PD. Pneumococcal cefotaxime susceptibility was 61.8% by CLSI (29.9%, EUCAST). Penicillin susceptibility was 69.4% by CLSI intravenous/EUCAST high-dose, but 6.3% using CLSI oral/EUCAST low-dose breakpoints. Tetracyclines, macrolides and trimethoprim/sulfamethoxazole had 5.6%-16.7% susceptibility.Among H. influenzae isolates, 59.7% were β-lactamase-negative, of which 87.7% and 74.6% were ampicillin-resistant (BLNAR) following EUCAST and CLSI criteria, respectively. H. influenzae fluoroquinolone, macrolide and tetracycline susceptibility reached 62.0%-89.5% (CLSI, EUCAST); macrolide susceptibility was 3.7%-5.8% (PK/PD). All were susceptible to ceftriaxone (all breakpoints) and cefotaxime (CLSI, PK/PD); cefotaxime susceptibility was 15.7% by EUCAST. H. influenzae amoxicillin/clavulanic acid susceptibility was 45.5% (EUCAST) and 32.5% (CLSI) but increased to 82.8% with high-dose (4 g/0.25 g/day, PK/PD). CONCLUSIONS: The hospitals showed high rates of penicillin-resistant S. pneumoniae and BLNAR H. influenzae. S. pneumoniae showed low susceptibility to macrolides and several cephalosporins. H. influenzae fluoroquinolone susceptibility was 88.0%-89.0% (CLSI). Future surveillance across Vietnam will help understand susceptibility trends over time and regions.
引用
- Torumkuney D, Van PH, Thinh LQ, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2020-21 in Vietnam: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277343. doi:10.1093/jac/dkaf290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。